Local administration of therapeutics by inhalation for treatment of lung diseases has the
ability to deliver drugs, nucleic acids and peptides specifically to the site of their action and …

Pulmonary tuberculosis is a highly prevalent respiratory disease that affects approximately a
quarter of the world's population. The drug treatment protocol for tuberculosis is complex …

This manuscript describes the preparation, characterization, and pharmacokinetic studies for
fluticasone and budesonide nanosuspensions in pulmonary delivery. A wet-milling method …

Pulmonary delivery of lipid-based nanotherapeutics by inhalation presents an
advantageous alternative to oral and intravenous routes of administration that avoids …

Nanotechnology provides new materials in the nanometer range with many potential
applications in clinical medicine and research. Due to their unique size-dependent …

Pulmonary delivery of active drugs has been applied for the treatment of obstructive lung
diseases, including asthma, chronic obstructive pulmonary disease and cystic fibrosis, for …

Drug delivery to the lungs by inhalation offers a targeted drug therapy for respiratory
diseases. However, the therapeutic efficacy of inhaled drugs is limited by their rapid …

The use of colloidal carrier systems for pulmonary drug delivery is an emerging field of
interest in nanomedicine. The objective of this study was to compare the pulmonary …

Cardiovascular diseases (CVDs) are the leading causes of morbidity and mortality
worldwide. However, despite the recent developments in the management of CVDs, the …

Traditional drugs are facing bottlenecks of lower solubility, absorption, and especially the
inefficient organs or cells targeting during the precision medicine era. It is urgently needed to …